|
[1] Boucher H, Miller L G, Razonable R R. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis, 2010, 51(Suppl 2):S183-197.
[2] Yoong P, Pier G B. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A, 2010, 107(5):2241-2246.
[3] Durai R, Ng P C, Hoque H. Methicillin-resistant Staphylococcus aureus: an update. AORN J, 2010, 91(5):599-606; quiz 607-599.
[4] Vernachio J H, Bayer A S, Ames B, et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother, 2006, 50(2):511-518.
[5] DeJonge M, Burchfield D, Bloom B, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr, 2007, 151(3):260-265, 265 e261.
[6] Weisman L E. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. Arch Pediatr, 2007, 14(Suppl 1):31-34.
[7] Burnie J P, Matthews R C, Carter T, et al. Identification of an Immunodominant ABC Transporter in methicillin-resistant Staphylococcus aureus infections. Infection and Immunity, 2000, 68(6):3200-3209.
[8] Weichhart T, Horky M, Söllner J, et al. Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro. Infection and Immunity, 2003, 71(8):4633-4641.
[9] Reilley S, Wenzel E, Reynolds L, et al. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother, 2005, 49(3):959-962.
[10] Weems J J, Steinberg J P, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother, 2006, 50(8):2751-2755.
[11] Arrecubieta C, Matsunaga I, Asai T, et al. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis, 2008, 198(4):571-575.
[12] Schaffer A C, Solinga R M, Cocchiaro J, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun, 2006, 74(4):2145-2153.
[13] Visai L, Xu Y, Casolini F, et al. Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a collagen substrate. J Biol Chem, 2000, 275(51):39837-39845.
[14] Benjamin D K, Schelonka R, White R, et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol, 2006, 26(5):290-295.
[15] Rupp M E, Holley H P, Lutz J, et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother, 2007, 51(12):4249-4254.
[16] Lalich I J, Sam-Agudu N A. Community-acquired methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a healthy adolescent male. Minn Med, 2010, 93(9):44-46.
[17] Maira-Litran T, Kropec A, Goldmann D A, et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun, 2005, 73(10):6752-6762.
[18] Gauduchon V, Cozon G, Vandenesch F, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis, 2004, 189(2):346-353.
[19] Ragle B E, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun, 2009, 77(7):2712-2718.
[20] LeClaire R D, Hunt R E, Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun, 2002, 70(5):2278-2281.
[21] Park J, Jagasia R, Kaufmann G F, et al. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol, 2007, 14(10):1119-1127.
|
